George M. Milne Jr. - 06 Jan 2022 Form 3 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role: Director
Signature: /s/ Joshua B. Cohen, as Attorney-in-Fact for George Mclean Milne
Issuer symbol: AMLX
Transactions as of: 06 Jan 2022
Net transactions value: $0
Form type: 3
Filing time: 06 Jan 2022, 16:03:43 UTC
Previous filing: 16 Jun 2021
Next filing: 08 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	AMLX	Common Stock						195,081	06 Jan 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	AMLX	Stock Option (Right to Buy)	06 Jan 2022	Common Stock	2,000	$6.88	Direct	F1
holding	AMLX	Series A Preferred Stock	06 Jan 2022	Common Stock	262,282		Direct	F2
holding	AMLX	Series B Preferred Stock	06 Jan 2022	Common Stock	384,449		Direct	F2
holding	AMLX	Series C-1 Preferred Stock	06 Jan 2022	Common Stock	19,482		Direct	F2
holding	AMLX	Series C-2 Preferred Stock	06 Jan 2022	Common Stock	23,212		Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	As of the date of this filing, 2,000 shares subject to such option vest and become exercisable in substantially equal monthly installments until February 19, 2022.
F2	Each share of Series A, Series B, Series C-1 and Series C-2 preferred stock (collectively the "Preferred Stock") is convertible on a one-for-one basis into Common Stock at any time at the election of the Reporting Person and will automatically convert upon the closing of the Issuer's initial public offering into the number of shares of the Issuer's Common Stock shown in column 3 without payment or further consideration. The Preferred Stock has no expiration date.

Content

As of the date of this filing, 2,000 shares subject to such option vest and become exercisable in substantially equal monthly installments until February 19, 2022.

Each share of Series A, Series B, Series C-1 and Series C-2 preferred stock (collectively the "Preferred Stock") is convertible on a one-for-one basis into Common Stock at any time at the election of the Reporting Person and will automatically convert upon the closing of the Issuer's initial public offering into the number of shares of the Issuer's Common Stock shown in column 3 without payment or further consideration. The Preferred Stock has no expiration date.